SMA Peg denied as experimental or investigational by Anthem?

Anthem's specific coverage criteria for sma peg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Anthem Denied This Claim — and Why It's Appealable

An "experimental or investigational" denial for a pegylated SMA therapy means Anthem has concluded that the treatment does not yet meet its internal criteria for established clinical benefit. However, when a therapy has received FDA approval for the relevant indication, the experimental classification is legally and clinically untenable, and the denial is virtually always overturned on appeal. Even for therapies under accelerated approval pathways, the FDA's regulatory finding of safety and effectiveness for the approved use provides a strong basis for reversal.

## Your Federal Appeal Rights

ACA §2719 guarantees an internal appeal and an independent external review by an IRO Anthem cannot control — and IROs apply a clinical-evidence standard that is independent of Anthem's internal policy. ERISA §503 adds the full-and-fair-review requirement. The external review window is generally four months from the denial date. Most state insurance codes also prohibit classifying FDA-approved therapies as experimental for the approved indication; cite your state's statute in the appeal. Expedited review is available if clinical deterioration is occurring.

## Concrete Appeal Steps

1. Confirm FDA approval status: Retrieve the full prescribing information and approval letter from the FDA's Drugs@FDA database and attach both to your appeal. 2. Obtain Anthem's experimental/investigational policy and identify each criterion the plan claims is unmet. 3. File Level 1 internal appeal with the FDA documentation and a prescriber letter responding point-by-point to each criterion. 4. Request external review simultaneously or immediately after Level 1 denial — IROs in experimental-therapy appeals focus heavily on FDA status and major guideline inclusion. 5. Cite your state insurance code provisions protecting access to FDA-approved therapies.

## Documentation to Gather

• FDA approval documentation: Prescribing information, approval letter, and any relevant FDA label update history.
• Guideline inclusion: Letter or excerpt showing the therapy is referenced in the applicable professional guideline organization's recommendations (e.g., relevant AAN, CureSMA, or neuromuscular specialty society guidance) — without citing specific statistics from those documents.
• Diagnosis and eligibility: Genetic confirmation of SMA and documentation that the patient falls within the FDA-approved population per the prescribing label.
• Prescriber medical-necessity letter: Explains why the therapy is the appropriate standard of care for this patient, citing the label and guideline organization, and directly refutes each of Anthem's experimental criteria.
• Prior treatment history: Chronological record of prior therapies with dates and outcomes, demonstrating the clinical context for this prescription.

## Criteria-Mapping Structure

For each of Anthem's experimental-criteria elements, write one entry: the criterion, the evidence that refutes it (FDA label section, guideline reference, chart note), and the source document. This structure leaves no ambiguity for the IRO reviewer.